Medtronic stock heads toward November 24 earnings update

Medtronic stock is heading toward a scheduled earnings checkpoint after the company confirmed that it will release its second-quarter fiscal 2027 results on Tuesday, November 24, 2026. The date was announced by Medtronic in a Medtronic press release dated November 4.

At 11:49:51 CET on Friday, November 13, the shares traded at 91.63 euros on Lang & Schwarz. The upcoming results therefore remain the next clearly defined company-specific event for investors following the stock.

November results set the next test

The November release will cover the second quarter of Medtronic's fiscal 2027 year. Investors are likely to focus on revenue momentum, profitability, cash generation and the outlook for the remainder of the fiscal year when the company reports.

The scheduled report follows a series of portfolio developments that have kept Medtronic in view. The company's recent announcements included an FDA label update for its Symplicity blood-pressure procedure and the expansion of its neurovascular offering with the Aristotle Mini Guidewire. Those developments provide operating context, but the November results will offer the next consolidated view of business performance.

Medtronic's medical-device portfolio spans cardiovascular, neuroscience, surgical and diabetes-related products. For shareholders, the key question is whether product launches and regulatory progress can translate into sustained sales growth while the company manages costs and invests in new platforms.

Investors can follow the broader US equity market through the S&P 500 market overview.

Further company-specific coverage is available in more news and analyses on Medtronic stock.